September 2026 clinical trial highlights
Research study participants are essential in the quest for new treatments and a cure for pulmonary fibrosis (PF).
Each month, we'll highlight a few of the many trials enrolling volunteers. All past issues are available on the PFF Clinical Trials Blog. To view more trials for various forms of interstitial lung disease (ILD), visit the 🔍 PFF Clinical Trial Finder.
Seeking participants with idiopathic pulmonary fibrosis (IPF)
Ifetroban in IPF
- Study ID: NCT05571059
- Trial Phase: Phase 2
- Intervention: Oral drug
- Sponsor: Cumberland Pharmaceuticals
- Study Contact: Ingrid Anderson, PhD, CCRP (615.627.4121, ianderson@cumberlandpharma.com)
Seeking participants for the PFF Community Registry
PFF Community Registry
- Study ID: NCT05382572
- Intervention: Observational
- Sponsor: Pulmonary Fibrosis Foundation
- Study Contact: Jessica E. Shore, PhD (312.818.5731; registry@pulmonaryfibrosis.org)
Seeking participants with systemic sclerosis associated with ILD (SSc-ILD)
BLISSc-ILD
- Study ID: NCT05878717
- Trial Phase: Phase 2/3
- Intervention: Subcutaneous injection
- Sponsor: GlaxoSmithKline
- Sponsor Contact: US GSK Clinical Trials Call Center (877.379.3718; GSKClinicalSupportHD@gsk.com)
Seeking participants with ILD
Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic ILD
- Study ID: NCT06751069
- Intervention: Pulmonary rehabilitation
- Sponsor: Mayo Clinic
- Sponsor Contact: Johanna Hoult, MA (507.293.1989; hoult.johanna@mayo.edu)
Putting a face to the science: living with IPF
.png?sfvrsn=2f77f248_1 "Clinical trial newsletter_2026.09_S. Fadler")
Steve noticed his lack of energy and continuous coughing. After living with these symptoms for one year, Steve was referred to a pulmonologist and underwent tests across three months to determine the root cause. After receiving his IPF diagnosis, Steve’s desire to contribute to the IPF community, and belief that clinical trial participants are essential to advancing research led him to participate in two clinical trials.
In the first study, Steve received a placebo. A placebo looks like medicine but has no active ingredients in it. A study that includes volunteers who receive the drug and another group who receive the placebo is an important way for researchers to measure how well the new drug will work. If you’re part of a trial that uses placebos, you won’t know which group you’re in, but you’ll be closely monitored throughout the study, even if you’re receiving a placebo.
The second study Steve participated in was discontinued. Researchers can still collect critical information even if a study ends earlier than expected. This is an essential part of the scientific discovery process and contributes toward the broader body of research.
Steve was inspired by the opportunity to advance the standard of care. He encourages others to get involved in research in similar ways.
To share your journey like Steve, complete the "My research study story" form.
 |
Phase 2 PH-ILD study meets its primary endpoint
intended.
The study demonstrated a greater reduction in pulmonary vascular resistance (PVR) in patients taking mosliciguat compared to placebo. PVR is the resistance that the blood has to overcome to flow through the blood vessels in the lungs.
Pulmovant will continue to evaluate mosliciguat as treatment in PH-ILD in the phase 3 PHrontier clinical trial.
The FDA grants LTI-03 Fast Track designation for IPF
In August 2026, Rein Therapeutics, Inc. announced the United States Food and Drug Administration (FDA) granted Fast Track designation to LTI-03. This designation is designed to advance the development and review of drugs which treat serious conditions to fill unmet medical needs. The purpose is to get important new drugs to patients earlier.
Watch the CTI Series recordings
If you have any questions or comments about this newsletter, please email partnerships@